Axogen, Inc. (AXGN)
| Market Cap | 2.96B +188.5% |
| Revenue (ttm) | 266.93M +24.3% |
| Net Income | -31.92M |
| EPS | -0.62 |
| Shares Out | 59.73M |
| PE Ratio | n/a |
| Forward PE | 71.69 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,046,432 |
| Open | 50.49 |
| Previous Close | 49.85 |
| Day's Range | 49.18 - 50.84 |
| 52-Week Range | 21.93 - 52.91 |
| Beta | 1.17 |
| Analysts | Strong Buy |
| Price Target | 59.09 (+19.37%) |
| Earnings Date | Oct 28, 2026 |
About AXGN
Axogen, Inc., together with its subsidiaries, engages in the development and commercialization of the technologies used for peripheral nerve regeneration and repair worldwide. The company offers Avance Nerve Graft, a processed nerve allograft intended for the surgical repair of peripheral nerve discontinuities; Axoguard Nerve Connector, a coaptation aid used to align and connect severed peripheral nerve ends in a tensionless repair; and Axoguard Nerve Protector, a product used to protect and wrap damaged peripheral nerves and reinforce reconstr... [Read more]
Financial Performance
In 2025, Axogen's revenue was $225.21 million, an increase of 20.21% compared to the previous year's $187.34 million. Losses were -$15.70 million, 57.6% more than in 2024.
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for AXGN stock is "Strong Buy." The 12-month stock price target is $59.09, which is an increase of 19.37% from the latest price.
News
Axogen, Inc. to Participate in Multiple Upcoming Investor Conferences
ALACHUA, Fla. and TAMPA, Fla., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of periphera...
AxoGen price target raised to $56 from $52 at Leerink
Leerink raised the firm’s price target on AxoGen (AXGN) to $56 from $52 and keeps an Outperform rating on the shares following the company’s Q3 earnings. After yet another strong…
AxoGen price target raised to $58 from $55 at Lake Street
Lake Street raised the firm’s price target on AxoGen (AXGN) to $58 from $55 and keeps a Buy rating on the shares after “a solid beat and guide up” in…
AxoGen price target raised to $65 from $58 at Mizuho
Mizuho raised the firm’s price target on AxoGen (AXGN) to $65 from $58 and keeps an Outperform rating on the shares.
AxoGen price target raised to $60 from $55 at Canaccord
Canaccord raised the firm’s price target on AxoGen (AXGN) to $60 from $55 and keeps a Buy rating on the shares. The firm said they posted an impressive Q against…
AxoGen price target raised to $56 from $53 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on AxoGen (AXGN) to $56 from $53 and keeps a Buy rating on the shares following the Q3 report. The company is on…
AxoGen price target raised to $60 from $50 at Barclays
Barclays analyst Christopher Pasquale raised the firm’s price target on AxoGen (AXGN) to $60 from $50 and keeps an Overweight rating on the shares. The company’s “strong” Q3 report shows…
AxoGen price target raised to $60 from $55 at Jefferies
Jefferies raised the firm’s price target on AxoGen (AXGN) to $60 from $55 and keeps a Buy rating on the shares following Q3 results. AxoGen has commenced pricing and yield…
Axogen Earnings Call Transcript: Q3 2026
Q3 revenue grew 26.2% YoY, with adjusted EBITDA margin reaching 17.7%. FY 2026 revenue guidance rose to at least $290M, while BioCircuit integration and near-term gross-margin pressure remain key considerations.
Axogen Slides: Q3 2026
Axogen has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on October 28, 2026.
Axogen Earnings release: Q3 2026
Axogen released its Q3 2026 earnings on October 28, 2026, summarizing the period's financial results.
Axogen Quarterly report: Q3 2026
Axogen has published its Q3 2026 quarterly earnings report on October 28, 2026.
Axogen Slides: Corporate presentation
Axogen has posted slides in relation to its latest quarterly earnings report, which was published on October 28, 2026.
AxoGen raises FY26 revenue view to at least $290M from at least $279M
Consensus $285.6M. The company said, “For 2026, we expect full-year revenue of at least $290 million, representing growth of at least 29%, including at least $7 million revenue from the…
AxoGen reports Q3 adjusted EPS 21c, consensus 13c
Reports Q3 revenue $75.83M, consensus $73.19M. “We are delighted with our third-quarter and year-to-date revenue performance and the progress we continue to make across each of Axogen’s (AXGN) strateg...
Axogen, Inc. Reports Third Quarter 2026 Financial Results
Raises Full Year Revenue Guidance to at Least 29% Growth or $290 million Raises Full Year Revenue Guidance to at Least 29% Growth or $290 million
AxoGen price target lowered to $50 from $55 at Barclays
Barclays lowered the firm’s price target on AxoGen (AXGN) to $50 from $55 and keeps an Overweight rating on the shares. The firm says its scenario analysis indicates the BioCircuit…
Axogen, Inc. to Report Third Quarter 2026 Financial Results on October 28, 2026
ALACHUA, Fla. and TAMPA, Fla.
AxoGen initiated with a Buy at BofA
BofA initiated coverage of AxoGen (AXGN) with a Buy rating and $52 price target As the “only company” with a full nerve repair suite and differentiated allograft solution, the firm…
AxoGen initiated with an Overweight at Barclays
Barclays initiated coverage of AxoGen (AXGN) with an Overweight rating and $55 price target The firm rolled out coverage of the medical suppliers and devices group with a Positive rating.
AxoGen should be bought on weakness, says Lake Street
Lake Street expects consistent execution from core Axogen (AXGN) to be complemented by Nerve Tape and recent new commercial wins and thinks consistent execution and outperformance can support multiple...
Axogen Completes Acquisition of BioCircuit Technologies, Adding NerveTape™, the First FDA Cleared Device for Sutureless Peripheral Nerve Repair
ALACHUA, Fla. and TAMPA, Fla.
AxoGen price target lowered to $53 from $60 at Truist
Truist analyst Ravi Misra lowered the firm’s price target on AxoGen (AXGN) to $53 from $60 and keeps a Buy rating on the shares. The firm is adjusting its model…